PRODUCTS & SERVICES
We were honored to welcome the Prime Minister of the Slovak Republic, Eduard Heger, at the premises of MultiplexDX. The Prime Minister showed profound interest in innovative technologies and solutions during his visit.
Together with his team, he took a tour through our laboratories in which we designed and developed our RT-PCR tests. Afterward, they moved to our conference room, where our management team presented more details about our revolutionary diagnostic test, Multiplex8+, which is currently still in the development phase, and our plans to significantly contribute to more accurate diagnostics should lead to more personalized breast cancer treatment.
We appreciate the time the Prime Minister and his team devoted to us, considering our company one of the most innovative ones in our country.
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.